Clinical Trial Update: Study of Pembrolizumab and M032 (NSC 733972) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating pembrolizumab in combination with M032 for glioblastoma, anaplastic astrocytoma, and gliosarcoma, currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• M032 (NSC 733972)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1, Phase 2 | Status: RECRUITING